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Abstract 
Inflammatory myofibroblastic tumors (IMTs) are a rare cause of echo-poor pancreatic 
head enlargement. Histologically, IMTs are characterized by spindle-shaped 
myofibroblasts or fibroblasts accompanied by a mixed immune cell infiltration. The most 
common localizations of IMTs have been reported in lung, mesentery and omentum, 
especially in children and young adults. IMTs show infiltrating growth, multilocular 
appearance and also metastasis have been reported. Curative resection is the only 
therapeutic option so far. In the palliative situation, evident data and clear guidelines for 
this rare tumor entity are missing. We report on a 44-year-old male with an unresectable 
IMT of the pancreatic head causing recurrent episodes of acute pancreatitis that resulted 
in a chronic obstructive course of the disease. The patient entered a palliative 
therapeutic regimen including radiation therapy and antiinflammatory medication. In a 
regular follow-up of 12 months, he presented with stable disease after initial 
progression. This case of local progressive IMT of the pancreatic head was managed with 
a palliative therapeutic regimen and is discussed based on the current literature.  
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Introduction 
Inflammatory myofibroblastic tumors (IMTs) occur primarily in visceral and soft 
tissue of children and young adults and occur most frequently in the first two decades of 
life. The most common localizations of IMTs have been reported in lung, mesentery and 
omentum [1, 2]. The etiology of IMT is unknown, although infection by Epstein-Barr 
virus or human herpesvirus-8 and reactive IL-6 production have been observed in a 
number of cases and discussed as etiological factors [2, 3]. A localization of IMT in the 
pancreas is very rare and needs differentiation from pancreatic head enlargement due to 
chronic pancreatitis and pancreatic cancer. 
The macroscopic appearance of IMT is usually a well-circumscribed or multinodular, 
white, firm mass with a whorled fleshy cut surface [2]. Histologically, IMT is composed of 
spindle-shaped myofibroblasts or fibroblasts accompanied by a mixed inflammatory 
infiltrate of eosinophils, plasma cells, and lymphocytes [1, 2]. Necrosis, a central scar, 
osseous metaplasia, and psammomatous calcifications have been described. The 
symptoms of IMT are determined by the tumor site. If localized in the pancreatic head 
with obstruction of the main pancreatic duct, it results in acute and finally chronic 
obstructive pancreatitis. It is a condition that needs to be differentiated from pancreatic 
head enlargement due to chronic pancreatitis and pancreatic cancer. 
Here we present the case of a young male patient with a history of recurrent acute 
pancreatitis caused by an IMT of the pancreatic head. In contrast to most reported cases, 
surgical resection was not possible and a palliative therapeutic regimen including 
radiation therapy as well as antiinflammatory treatment was established with a regular 
follow-up of 12 months. 
Case Report 
A 44-year-old male presented to our outpatients department with a two-year history of recurrent 
acute pancreatitis of unknown etiology. He complained about recurrent upper abdominal pain, 
intermittent diarrhea, nausea, recurrent emesis and weight loss of 40 kg in the course of the last year. 
His family history was negative for any pancreatic or malignant disease.  
The patient’s past medical history had been inconspicuous until April 2006 when he was admitted to 
a regional hospital because of recurrent abdominal pain and jaundice. A first ERCP in that hospital 
revealed a stenosis of the distal common bile duct and a small concrement proximal to the stenosis. 
After endoscopic papillotomy and concrement extraction an endoprosthesis was inserted. The 
pancreatic duct was not visualized. In June 2006, the patient was scheduled for an elective surgical 
procedure because of the common bile duct stenosis of unknown etiology. A cholecystectomy was 
performed as there was cholecystolithiasis and a biliodigestive anastomosis was created revealing 
chronic inflammation of the resected common bile duct. The histological specimen of the common bile 
duct showed chronic granulomatous inflammation with low-grade dysplasia. 
Recurrent attacks of abdominal pain, nausea and emesis in the following months finally led to 
referral to the department of gastroenterology. Transabdominal ultrasound (fig. 1) revealed an 
echo-poor hypovascularized lesion in the pancreatic head, 60 × 40 mm in size, with a dilated main 
pancreatic duct up to 6 mm in the pancreatic corpus. Additionally, multiple peripancreatic lymph nodes 
8–10 mm in diameter were depicted in the peripancreatic mesenterium. Laboratory results showed a 
9-fold increase of lipase in combination with elevated markers of cholestasis and slightly elevated 
transaminases. The concentration of IgG-4 was below the normal range. Blood cell count, coagulation 
tests and C-reactive protein were within normal ranges. Exocrine pancreatic insufficiency was 
diagnosed by repeated measurements of pancreatic elastase in the stool and confirmed by 
13C-mixed-triglyceride breath test. Endocrine pancreatic insufficiency was ruled out. Contrast-enhanced  
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CT scan (fig. 2a) confirmed the findings of the transabdominal ultrasound with inhomogeneous 
pancreatic parenchyma in the pancreatic head, a hypodense lesion of almost 3 cm in size within the 
pancreatic head closely adjacent to the neighboring anatomic structures such as the portal vein, and a 
dilated main pancreatic duct in the pancreatic corpus and tail. Multiple lymph nodes with a maximum 
size of 24 mm were depicted in close neighborhood of the organ. There were no focal lesions in the 
hepatic parenchyma and no intrahepatic cholestasis. 
With a suspicion of malignant pancreatic head enlargement, the patient underwent surgery. 
Intraoperatively, the pancreatic head presented as a hard mass. The pancreatic body and tail showed 
fibrosis but less distinct than within the pancreatic head. Circumscribed necrosis of pancreatic 
parenchyma was visible. Preparation of the portal vein was not possible due to massive peripancreatic 
inflammation and multiple adhesions. As resection of the pancreatic head was technically impossible, a 
pancreaticogastrostomy was performed. 
Histological examination (fig. 3) showed an IMT with compact fascicular proliferation of spindled 
and plump myofibroblasts and fibroblasts. The biopsy contained myxoid, edematous, and collagenized 
regions as well as a distinctive inflammatory infiltrate of lymphocytes, plasma cells and eosinophils. 
Spindled cells showed a strong expression of cytoplasmatic vimentin and sm actin whereas 
immunreactivity of desmin, S100, cytokeratin, CD117, or ALK was not observed. Necrosis, cellular 
atypia, mitotic figures, or overexpression of p53 were not evident in the tissue. Histology was consistent 
with the diagnosis of an IMT. The adjacent pancreatic tissue was partly displaced by proliferating 
fibroblasts and collagen deposits. More distantly, there were periductular fibrosis and a scattered 
infiltrate of lymphocytes and histiocytes of the pancreatic tissue, leading to the diagnosis of chronic 
pancreatitis. No histological evidence of autoimmune pancreatitis was present. 
The short-term postoperative course was unremarkable. After a follow-up of 3 months, the patient 
presented with aggravating abdominal pain and weight loss of 10 kg despite pancreatic enzyme 
supplementation. CT scan after another 6 months (fig. 2b) revealed a large tumor mass comprising the 
pancreatic head, liver hilus and mesenteric vessels. Symptomatically, the patient complained about 
non-infectious diarrhea due to exocrine pancreatic insufficiency and ischemic condition presenting with 
typical ischemic left colonic lesions and ischemic duodenitis. Lacking evidence-based guidelines, we 
decided to perform radiation therapy (20/2 Gy) and antiinflammatory medical therapy starting with 
60 mg prednisolone per day that was tapered down. After another 3 months, the patient presented 
well-being in our outpatient department. Pain was symptomatically treated and controlled with 
novaminsulfon and a low-potent opioid (tramadol), stool frequency was stable and he gained 8 kg of 
weight. CT scan showed at least a stable tumor mass (fig. 2c) and the patient was scheduled for 
follow-up. 
Discussion 
In case of recurrent acute pancreatitis of unknown etiology and echo-poor pancreatic 
head enlargement, ductal adenocarcinoma is always an important differential diagnosis. 
Clinically and morphologically, the very rare IMT resembles pancreatic adenocarcinoma 
as well as inflammatory lesions related to autoimmune pancreatitis or malignant fibrous 
histiocytoma.  
For several decades the term ‘inflammatory pseudotumor’ summarized a wide range of 
reactive and neoplastic lesions. During the last decade the diagnosis and characterization 
of IMT has been optimized by distinct pathological and molecular features. The World 
Health Organization classifies this rare tumor entity as a distinctive neoplasm of 
intermediate biological potential [4]. Especially the discovery of cytogenetic aberrations in 
IMT and the recognition of ALK gene rearrangements solidified the concept of IMT as a 
neoplastic lesion [5]. It most frequently occurs in the lung or the mesenterium of children 
or young adults and rarely (<5%) metastasizes [5, 6].  
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In a large study of IMTs by Coffin et al. [2], extrapulmonary IMTs were described to be 
larger and less well-circumscribed than pulmonary IMTs. Adjacent organs are more often 
involved, which reduces the opportunity for complete resection and leads to a recurrence 
rate of approximately 25% related to resectability, multinodularity, and location. 
Only 28 cases of pancreatic IMT have been reported so far [7, 8], 60% being located in 
the pancreatic head (table 1). Histological diagnosis in biopsies or intraoperative frozen 
sections is difficult and IMTs must be differentiated from inflammatory pseudotumors 
due to autoimmune pancreatitis [9] or chronic pancreatitis, fibrosarcoma, pancreatic 
carcinoma and lymphoma [10], as their therapies differ substantially. The low incidence 
of IMT of the pancreas and the synonymous use of the terms IMT and inflammatory 
pseudotumor make it even more difficult to give consistent information on epidemiology, 
clinical presentation and prognosis of this tumor entity. 
Here we report the case of a young male with a history of chronic pancreatitis due to 
recurrent episodes of acute pancreatitis caused by an IMT in the pancreatic head. In 
contrast to the majority of cases in the literature (table 1), curative resection was 
impossible. The two-year history of recurrent attacks of acute pancreatitis and of a 
stenosis of the common bile duct with histopathologic signs of chronic inflammation 
leads to the assumption that the tumor developed over a longer period of time.  
Besides surgical resection, alternative therapeutic regimes are still lacking. While 
systemic immunosuppressive treatment with steroids has been reported for 
extrapancreatic IMTs, there is only one reported case of IMT localized in the pancreatic 
head in a pediatric patient [11] that was treated with a palliative approach. In our patient 
we decided to perform palliative radiation for local tumor treatment combined with 
antiinflammatory medical treatment as an individualized approach. The patient has been 
included in a regular follow-up of 12 months up to now. Radiation therapy and corticoid 
medication might be discussed for alternative and symptomatic treatment but cannot be 
recommended as a standard regimen for palliative therapy. Close follow-up and 
symptomatic therapy are the basic therapeutic modalities that hopefully can be 
complemented by an effective medical therapy in future. 
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Table 1. Case reports of pancreatic IMT displaying age at time of diagnosis, gender, tumor size and 
localization, therapy and follow-up 
Reference  Age  
(years) 
Gender  Tumor size  
(CT/US) 
Localization  Therapy  Follow-up 
Johnson et al. [12]  29  F  10 cm  pancreatic head  resection  relapse after 8 months 
Abrebanel et al. [13]  12  F  12 cm  pancreatic body  resection  2 years, curative 
Scott et al. [14]  2.5  F  13 cm  pancreatic body  resection  6 years, curative 
Palazzo and Chang [15]  52  F  3 cm  pancreatic tail  resection  6 months, curative 
Uzoaru et al. [16]  8   F  3 cm   pancreatic head  resection  4.5 years, curative 
Kroft et al. [17]  39  F  7 cm  pancreatic body  resection  6 months, curative 
Qanadli et al. [18]  29  M  12 cm   pancreatic tail  resection  5 months, curative 
Shankar et al. [19]  8  F  10.7 cm  pancreatic body and tail  resection  2 years, curative 
Petter et al. [20]  64  M  5 cm  pancreatic head  resection  4 years, curative 
Morris-Stiff et al. [21]  11  M  10 cm  pancreatic body and tail  resection  3 years, curative 
McClain et al. [22]  11  F  3.4 cm  pancreatic head  resection  not available 
Liu and Consorti [23]  54  F  5 cm  pancreatic head  resection  2 years, curative 
Walsh et al. [24]  35  M  5 cm   pancreatic head  resection  relapse with lung 
metastasis after 6 years 
Zanger et al. [25]  62  F  4.5 cm  pancreatic head  resection  6 months, curative 
Yamamoto et al. [26]  55  M  1.5 cm  pancreatic head  resection  28 months, curative 
Slavotinek et al. [27]  4  F  3 cm  pancreatic head  resection  4 years, curative 
Esposito et al. [28]  69  M  tumor mass  pancreatic body and tail  resection  7 months† 
Pungpapong et al. [7]  70  M  3.8 cm  pancreatic tail  resection  10 months, curative 
Wreesman et al. [29]  62  M  3 cm  pancreatic head  resection  6 years, curative 
  56  M  not available  pancreatic head  resection  5 years, curative 
  50  M  5 cm   pancreatic head  resection  4 years, curative 
  57  F  not available  pancreatic head  resection  3 years, curative 
  45  M  no mass lesion identified  pancreatic head  resection  10 years, curative 
  32  F  2.5 cm   pancreatic head  resection  12 years, curative 
Stringer et al. [30]  5  F  7 cm  pancreatic body  resection  9 months, curative 
 
 
 
 
 
Fig. 1. Transabdominal ultrasound (Philips, 2D 35 Hz) revealing an echo-poor pancreatic head 
enlargement (1) and consecutive dilatation of the pancreatic duct (pd). The pancreatic tail presented 
with unsuspicious parenchyma, whereas small calcifications (c) were visible in the pancreatic head. 
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Fig. 2. CT scan images documenting tumor size and spread (1) at diagnosis (a), 6 months after 
diagnosis (b) and another 3 months after radiation and corticoid therapy (c). At diagnosis, consecutive 
dilatation of the pancreatic duct (pd) was visible secondary to the pancreatic head enlargement. CT 
scan did not reveal typical morphological signs of advanced chronic pancreatitis [pancreatic 
parenchyma (p) and splenic artery and vein (sa)]. Follow-up after 3 months (b) presented a diffuse 
tumor mass comprising the pancreatic head, liver and mesenteric arteries. After radiation and corticoid 
therapy (c), a partial response of the tumor mass was visible. No metastases were detected. 
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Fig. 3. Panels of H&E staining (a) and immunohistochemical staining of vimentin (b) and LCA 
(leukocytic common antigen; CD45) (c) demonstrating replacement of the pancreatic tissue (P) by 
IMT with compression of the ductuli (D, ĺ), fibrosis (F) and sparse infiltration of lymphocytes. High 
magnification showed a compact spindle proliferation with fascicular and storiform pattern (d) and a 
polymorphous inflammatory infiltrate with predominant eosinophils (g, ĺ), lymphocytes (h), and 
plasma cells (i). Biopsy of the duodenum showed ischemic changes with irregularity, atrophy and 
regenerative atypies of the epithelium (j). Spindle cells showed diffuse cytoplasmatic immunoreactivity 
of vimentin (b, e) and sm actin (f) (microscope: Zeiss Axioscope 50, camera: Nikon coolpix 990; 
magnification: ×200, ×400). 
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